中金资本领投，辅助生殖企业「瑞辅达医疗」完成数千万元B轮融资

Core Viewpoint - Ruifuda Medical has recently completed a Series B financing round of several tens of millions, led by a fund managed by CICC Capital, with participation from the Lianyungang Economic and Technological Development Zone Industrial Fund. The funds will primarily be used for technology research and development, market expansion, capacity upgrades, and team building [1] Group 1: Company Overview - Ruifuda Medical, established in 2018, focuses on the research and development of consumables and reagents in the assisted reproductive field. The founder, Fu Yang, has over 20 years of experience in the industry and has been involved in the entire process from laboratory product development to industrialization [1] - The company’s product pipeline covers key areas in in vitro fertilization (IVF), including low-temperature storage, embryo culture, and in vitro fertilization processes [1] Group 2: Product Development - In March of this year, Ruifuda Medical's core patented product, a closed vitrification rod for assisted reproductive embryo freezing technology, was officially approved for market launch. This technology reduces freezing damage and extends storage periods by creating a non-crystalline glass state at ultra-low temperatures [2] - The closed vitrification rod addresses two critical issues in the freezing process: rapid cooling and contamination prevention. It utilizes a unique liquid refrigerant design to achieve cooling rates comparable to open rods while effectively isolating samples from direct contact with liquid nitrogen [2] Group 3: Market Expansion and Recognition - As product development matures, Ruifuda Medical is gradually advancing its market promotion. In April, the company’s self-developed vitrification and thawing liquid set received FDA registration approval in the United States. The company aims to accelerate domestic market entry and capacity expansion while significantly expanding into international markets [4] - To date, Ruifuda Medical has filed six invention patents and successfully obtained recognition as a national high-tech enterprise as of March 2025 [4] Group 4: Investor and Company Perspectives - CICC Capital expressed that Ruifuda Medical demonstrates strong R&D capabilities and efficient industrialization in the assisted reproduction sector, positioning it as a leader in domestic medical devices. The investment aims to support the company in building stronger technological barriers and broader market prospects [5] - Ruifuda Medical views this Series B financing as a critical milestone in its development, marking an important step towards higher standards in domestic assisted reproductive devices. The company plans to continue driving technological innovation, enhancing quality control, and improving service capabilities for global application of its core products [5]